피임약 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of contraceptives Market

The global contraceptives market size was valued at USD 33.42 billion in 2025 and is projected to grow from USD 35.83 billion in 2026 to USD 62.49 billion by 2034, exhibiting a CAGR of 7.20% during the forecast period. North America dominated the global contraceptives market with a 43.17% share in 2025. Growing awareness of family planning, increasing access to birth control products, government-supported reproductive health programs, and rising demand for effective pregnancy-prevention methods are supporting market expansion.

Contraception includes drugs, devices, and procedures used to prevent unintended pregnancies. Increasing awareness regarding reproductive health and women's autonomy is encouraging consumers to consider a broader range of contraceptive options. Government initiatives in developing economies are also improving access to family planning services and modern contraceptive methods.

Market Definition and Scope

The contraceptives market includes pharmaceutical and medical-device products used for pregnancy prevention. The market is broadly segmented by product, gender, and distribution channel. Products include contraceptive drugs and contraceptive devices, while distribution channels comprise retail pharmacies, hospital pharmacies, and online channels. The market serves both male and female users and includes hormonal and non-hormonal contraceptive solutions.

Market Dynamics

DRIVER - Rising Awareness and Government Family Planning Initiatives

Increasing awareness about unwanted pregnancies and reproductive health is a major market driver. Governments and healthcare organizations are expanding family planning campaigns, educational programs, and access to contraceptive services. Such initiatives are particularly important in developing countries, where improved awareness and healthcare access can increase adoption of modern birth control methods.

TRENDS - Increasing Demand for Low-Dose Combined Oral Contraceptives

Low-dose combined oral contraceptives are gaining attention because they contain lower quantities of estrogen than older formulations. Continued clinical research is supporting the development of contraceptive options with improved effectiveness and tolerability. At the same time, digital health platforms and telemedicine services are making contraceptive consultation and prescription access more convenient.

RESTRAINT - Side Effects Associated with Contraceptive Products

Potential side effects associated with certain contraceptive methods can restrict adoption. Oral contraceptives may cause symptoms such as nausea, headaches, or migraine in some users. Concerns regarding tolerability, safety, and suitability can influence consumer preferences and encourage some individuals to select alternative contraceptive methods.

Impact of COVID-19

The COVID-19 pandemic disrupted healthcare services, pharmaceutical supply chains, clinical activities, and routine reproductive healthcare in several countries. Restrictions on movement and reduced access to healthcare facilities affected contraceptive consultations and distribution. However, increased adoption of telemedicine, online consultations, and digital prescription services created alternative channels for accessing contraceptive products. As healthcare services normalized, demand recovered alongside renewed family planning activities.

Segmentation Analysis

By Product

Contraceptive drugs represent the leading product category due to widespread awareness, established distribution networks, and availability of oral contraceptive products. Increasing pharmaceutical development and product launches are supporting the segment. Meanwhile, contraceptive devices are expected to expand as consumers seek long-acting and alternative birth control options.

By Gender

The market is divided into male and female segments. The female segment continues to represent a significant portion of demand due to the broad availability of female contraceptive products and continuing efforts to reduce unintended pregnancies. The male segment is also gaining attention as pharmaceutical companies and researchers develop additional male contraceptive solutions.

By Distribution Channel

Retail pharmacies are expected to maintain the leading position because of their extensive distribution networks and convenient consumer access. Hospital pharmacies remain important for contraceptive devices and prescription-based products. Online channels are gaining momentum as digital healthcare platforms improve access to consultations, prescriptions, and contraceptive products.

Regional Analysis

North America

North America dominated the market in 2025 with a market value of USD 9.71 billion. Strong contraceptive awareness, established healthcare infrastructure, extensive product availability, and increasing attention toward preventing unintended pregnancies support regional demand.

Europe

Europe is expected to witness steady growth, supported by clinical research, contraceptive adoption, healthcare initiatives, and increasing availability of modern birth control products. The region is projected to grow at a 5.6% CAGR during the forecast period.

Asia Pacific

Asia Pacific is expected to experience significant growth due to rising awareness regarding family planning, increasing healthcare accessibility, and government initiatives promoting reproductive health. Growing participation of manufacturers in Asian markets is also creating new opportunities.

U.S.

The U.S. market benefits from high contraceptive awareness, established healthcare infrastructure, government-supported reproductive health initiatives, and broad availability of contraceptive products.

Japan

The contraceptives market in Japan is expected to reach USD 1.05 billion by 2025, supported by established healthcare services and increasing availability of contraceptive options.

China

China is expected to witness strong market growth, supported by healthcare development, increasing awareness, and improving access to family planning products and services.

Competitive Landscape

The market is characterized by the presence of pharmaceutical companies, medical-device manufacturers, and specialized reproductive-health companies. Leading participants focus on product development, regulatory approvals, distribution expansion, and digital healthcare partnerships. Key companies include Pfizer Inc., Bayer AG, CooperSurgical Inc., The Female Health Company, Teva Pharmaceutical Industries Limited, Merck & Co., Inc., Mayer Laboratories, Inc., Church & Dwight Co., Inc., and Medisafe Distribution Inc.

Key Industry Developments

Recent industry activity has focused on prescription delivery, telemedicine, digital contraceptive solutions, and novel pharmaceutical formulations. Mayne Pharma received U.S. FDA approval for NEXTSTELLIS in 2021, while Emme expanded its contraceptive technology platform into prescription delivery and telemedicine services. Other developments include digital fertility-management and non-hormonal contraceptive products.

Report Coverage

The contraceptives market report provides qualitative and quantitative analysis of market size and market value across product categories, gender groups, distribution channels, and major geographic regions. It examines market drivers, restraints, trends, growth opportunities, competitive strategies, product launches, clinical developments, and regional market conditions. The report also profiles leading companies operating in the global contraceptives industry.

Conclusion

The global contraceptives market is projected to expand from USD 33.42 billion in 2025 to USD 35.83 billion in 2026 and USD 62.49 billion by 2034. Increasing awareness of reproductive health, government-supported family planning programs, continued development of contraceptive drugs and devices, and growing access through retail and digital healthcare channels will support market growth. North America will remain a major market, while Asia Pacific is expected to offer substantial opportunities as healthcare access and awareness improve. Continued innovation in low-dose, non-hormonal, male, and digitally supported contraceptive solutions is expected to strengthen the industry's long-term outlook.

By Product

• Contraceptive Drugs
  • Oral
  • Injectable
  • Patches
• Contraceptive Devices
  • Male Contraceptive Devices
  • Female Contraceptive Devices

By Gender

• Male
• Female

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Clinics
• Online Channel
• Public Channel & NGO
• Others

By Geography

• North America
  • By Product
  • By Gender
  • By Distribution Channel
  • By Country
• Europe
  • By Product
  • By Gender
  • By Distribution Channel
  • By Country
• Asia Pacific
  • By Product
  • By Gender
  • By Distribution Channel
  • By Country
• Latin America
  • By Product
  • By Gender
  • By Distribution Channel
  • By Country
• Middle East & Africa
  • By Product
  • By Gender
  • By Distribution Channel
  • By Country

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Recent Industry Developments Such as Mergers & Acquisitions
• 4.2. Regulatory Scenario for Key Countries
• 4.3. New Service/Product Launch
• 4.4. Technological Developments
• 4.5. Key Industry Trends

5. Global Contraceptives Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Contraceptive Drugs
    • 5.2.1.1. Oral
    • 5.2.1.2. Injectable
    • 5.2.1.3. Patches
  • 5.2.2. Contraceptive Devices
    • 5.2.2.1. Male Contraceptive Devices
    • 5.2.2.2. Female Contraceptive Devices
• 5.3. Market Analysis, Insights and Forecast - By Gender
  • 5.3.1. Male
  • 5.3.2. Female
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospital Pharmacy
  • 5.4.2. Retail Pharmacy
  • 5.4.3. Online Channel
  • 5.4.4. Public Channel & NGOs
  • 5.4.5. Clinics
  • 5.4.6. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Contraceptives Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Contraceptive Drugs
    • 6.2.1.1. Oral
    • 6.2.1.2. Injectable
    • 6.2.1.3. Patches
  • 6.2.2. Contraceptive Devices
    • 6.2.2.1. Male Contraceptive Devices
    • 6.2.2.2. Female Contraceptive Devices
• 6.3. Market Analysis, Insights and Forecast - By Gender
  • 6.3.1. Male
  • 6.3.2. Female
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospital Pharmacy
  • 6.4.2. Retail Pharmacy
  • 6.4.3. Online Channel
  • 6.4.4. Public Channel & NGOs
  • 6.4.5. Clinics
  • 6.4.6. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Contraceptives Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Contraceptive Drugs
    • 7.2.1.1. Oral
    • 7.2.1.2. Injectable
    • 7.2.1.3. Patches
  • 7.2.2. Contraceptive Devices
    • 7.2.2.1. Male Contraceptive Devices
    • 7.2.2.2. Female Contraceptive Devices
• 7.3. Market Analysis, Insights and Forecast - By Gender
  • 7.3.1. Male
  • 7.3.2. Female
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospital Pharmacy
  • 7.4.2. Retail Pharmacy
  • 7.4.3. Online Channel
  • 7.4.4. Public Channel & NGOs
  • 7.4.5. Clinics
  • 7.4.6. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/Sub Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Spain
  • 7.5.5. Italy
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Contraceptives Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Contraceptive Drugs
    • 8.2.1.1. Oral
    • 8.2.1.2. Injectable
    • 8.2.1.3. Patches
  • 8.2.2. Contraceptive Devices
    • 8.2.2.1. Male Contraceptive Devices
    • 8.2.2.2. Female Contraceptive Devices
• 8.3. Market Analysis, Insights and Forecast - By Gender
  • 8.3.1. Male
  • 8.3.2. Female
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospital Pharmacy
  • 8.4.2. Retail Pharmacy
  • 8.4.3. Online Channel
  • 8.4.4. Public Channel & NGOs
  • 8.4.5. Clinics
  • 8.4.6. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/Sub Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Contraceptives Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Contraceptive Drugs
    • 9.2.1.1. Oral
    • 9.2.1.2. Injectable
    • 9.2.1.3. Patches
  • 9.2.2. Contraceptive Devices
    • 9.2.2.1. Male Contraceptive Devices
    • 9.2.2.2. Female Contraceptive Devices
• 9.3. Market Analysis, Insights and Forecast - By Gender
  • 9.3.1. Male
  • 9.3.2. Female
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospital Pharmacy
  • 9.4.2. Retail Pharmacy
  • 9.4.3. Online Channel
  • 9.4.4. Public Channel & NGOs
  • 9.4.5. Clinics
  • 9.4.6. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/Sub Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Contraceptives Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. Contraceptive Drugs
    • 10.2.1.1. Oral
    • 10.2.1.2. Injectable
    • 10.2.1.3. Patches
  • 10.2.2. Contraceptive Devices
    • 10.2.2.1. Male Contraceptive Devices
    • 10.2.2.2. Female Contraceptive Devices
• 10.3. Market Analysis, Insights and Forecast - By Gender
  • 10.3.1. Male
  • 10.3.2. Female
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospital Pharmacy
  • 10.4.2. Retail Pharmacy
  • 10.4.3. Online Channel
  • 10.4.4. Public Channel & NGOs
  • 10.4.5. Clinics
  • 10.4.6. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/Sub Region
  • 10.5.1. GCC Countries
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2021)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Pfizer, Inc.
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products & services,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Bayer AG
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products & services,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. strategies,
    • 11.5.2.5. financials (based on availability)
  • 11.5.3. Cooper Surgical, Inc.
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products & services,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. The Female Health Company
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products & services,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Teva Pharmaceutical Industries Limited
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products & services,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. Merck & Co., Inc.
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products & services,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Mayer Laboratories, Inc
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products & services,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Church & Dwight, Co., Inc.
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products & services,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. Medisafe Distribution Inc.
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products & services,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Others
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products & services,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)

12. Strategic Recommendations